Basic Information
| RNALocate ID: | RLID:11003016 |
| RNA Symbol: | hsa-miR-497-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-497 |
| RNA ID: | miRBase:MIMAT0002820 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002346 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002347 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002348 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11003013 | Exosome | Brain tissue | 23382797 |
| RLID:11003014 | Exosome | Plasma | 23663360 |
| RLID:11003015 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
| RLID:11003017 | Microvesicle | Follicular fluid | 23666971 |
| RLID:11003018 | Microvesicle | Hepatoma cells | 23771658 |
| RLID-D:11000155 | Exosome | Mast cells | |
| RLID-D:11000487 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-497-5p | Diffuse large b cell lymphoma | MNDR-E-MI-54882 |
| MNDR | hsa-miR-497-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-54883 |
| MNDR | hsa-miR-497-5p | Oral squamous cell carcinoma | MNDR-E-MI-54884 |
| MNDR | hsa-miR-497-5p | Large cell neuroendocrine cancer | MNDR-E-MI-54885 |
| MNDR | hsa-miR-497-5p | Medulloblastoma | MNDR-E-MI-54886 |
| MNDR | hsa-miR-497-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-54887 |
| MNDR | hsa-miR-497-5p | Lymphoma | MNDR-E-MI-54888 |
| MNDR | hsa-miR-497-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-54889 |
| MNDR | hsa-miR-497-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-54890 |
| MNDR | hsa-miR-497-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-54891 |
| MNDR | hsa-miR-497-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-54892 |
| MNDR | hsa-miR-497-5p | Her2-receptor positive breast cancer | MNDR-E-MI-54893 |
| MNDR | hsa-miR-497-5p | Breast cancer luminal | MNDR-E-MI-54894 |
| MNDR | hsa-miR-497-5p | Prostate cancer | MNDR-E-MI-54895 |
| MNDR | hsa-miR-497-5p | Gastric cancer | MNDR-E-MI-54896 |
| MNDR | hsa-miR-497-5p | Alzheimer disease | MNDR-E-MI-54897 |
| MNDR | hsa-miR-497-5p | Intracranial aneurysm | MNDR-E-MI-54898 |
| MNDR | hsa-miR-497-5p | Bladder cancer | MNDR-E-MI-54899 |
| MNDR | hsa-miR-497-5p | Esophageal carcinoma | MNDR-E-MI-54900 |
| MNDR | hsa-miR-497-5p | Sarcoma | MNDR-E-MI-54901 |
| MNDR | hsa-miR-497-5p | Seizures | MNDR-E-MI-54902 |
| MNDR | hsa-miR-497-5p | Head and neck cancer | MNDR-E-MI-54903 |
| MNDR | hsa-miR-497-5p | Cardiovascular disease | MNDR-E-MI-54904 |
| MNDR | hsa-miR-497-5p | Lung cancer | MNDR-E-MI-54905 |
| MNDR | hsa-miR-497-5p | Parkinson disease | MNDR-E-MI-54906 |
| MNDR | hsa-miR-497-5p | Basal-like breast cancer | MNDR-E-MI-54907 |
| MNDR | hsa-miR-497-5p | Neuroendocrine neoplasia | MNDR-E-MI-54908 |
| MNDR | hsa-miR-497-5p | Thyroid cancer | MNDR-E-MI-54909 |
| MNDR | hsa-miR-497-5p | Pituitary neoplasms | MNDR-E-MI-54910 |
| MNDR | hsa-miR-497-5p | Pancreatic cancer | MNDR-E-MI-54911 |
| MNDR | hsa-miR-497-5p | Malignant melanoma | MNDR-E-MI-54912 |
| MNDR | hsa-miR-497-5p | Rectum adenocarcinoma | MNDR-E-MI-54913 |
| MNDR | hsa-miR-497-5p | Nephroblastoma | MNDR-E-MI-54914 |
| MNDR | hsa-miR-497-5p | Colon cancer | MNDR-E-MI-54915 |
| MNDR | hsa-miR-497-5p | Colon adenocarcinoma | MNDR-E-MI-54916 |
| MNDR | hsa-miR-497-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-54917 |
| MNDR | hsa-miR-497-5p | Familial ovarian cancer | MNDR-E-MI-54918 |
| MNDR | hsa-miR-497-5p | Carcinoma ductal breast | MNDR-E-MI-54919 |
| MNDR | hsa-miR-497-5p | Invasive ductal carcinoma | MNDR-E-MI-54920 |
| MNDR | hsa-miR-497-5p | Glioblastoma | MNDR-E-MI-54921 |
| MNDR | hsa-miR-497-5p | Astrocytoma | MNDR-E-MI-54922 |
| MNDR | hsa-miR-497-5p | Glioma | MNDR-E-MI-54923 |
| MNDR | hsa-miR-497-5p | Chordoma | MNDR-E-MI-54924 |
| MNDR | hsa-miR-497-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-54925 |
| MNDR | hsa-miR-497-5p | Temporal lobe epilepsy | MNDR-E-MI-54926 |
| MNDR | hsa-miR-497-5p | Osteosarcoma | MNDR-E-MI-54927 |
| MNDR | hsa-miR-497-5p | Breast carcinoma | MNDR-E-MI-54928 |
| MNDR | hsa-miR-497-5p | Meningioma | MNDR-E-MI-54929 |
| MNDR | hsa-miR-497-5p | Gastric adenocarcinoma | MNDR-E-MI-54930 |
| MNDR | hsa-miR-497-5p | Cervical squamous cell carcinoma | MNDR-E-MI-54931 |
| MNDR | hsa-miR-497-5p | Pituitary adenoma | MNDR-E-MI-54932 |
| MNDR | hsa-miR-497-5p | Lung squamous cell carcinoma | MNDR-E-MI-54933 |
| MNDR | hsa-miR-497-5p | Lung adenocarcinoma | MNDR-E-MI-54934 |
| MNDR | hsa-miR-497-5p | Adrenocortical cancer | MNDR-E-MI-54935 |
| MNDR | hsa-miR-497-5p | Thyroid carcinoma | MNDR-E-MI-54936 |
| MNDR | hsa-miR-497-5p | Bladder urothelial carcinoma | MNDR-E-MI-54937 |
| MNDR | hsa-miR-497-5p | Pancreatic adenocarcinoma | MNDR-E-MI-54938 |
| MNDR | hsa-miR-497-5p | Cervical cancer | MNDR-E-MI-54939 |
| MNDR | hsa-miR-497-5p | Carcinoma renal cell | MNDR-E-MI-54940 |
| MNDR | hsa-miR-497-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-54941 |
| MNDR | hsa-miR-497-5p | Clear cell renal cell carcinoma | MNDR-E-MI-54942 |
| MNDR | hsa-miR-497-5p | Chromophobe renal cell carcinoma | MNDR-E-MI-54943 |
| MNDR | hsa-miR-497-5p | Large cell carcinoma | MNDR-E-MI-54944 |
| MNDR | hsa-miR-497-5p | Cholangiocarcinoma | MNDR-E-MI-54945 |
| MNDR | hsa-miR-497-5p | Esophageal cancer | MNDR-E-MI-54946 |
| MNDR | hsa-miR-497-5p | Lung small cell carcinoma | MNDR-E-MI-54947 |
| MNDR | hsa-miR-497-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-54948 |
| MNDR | hsa-miR-497-5p | Testicular germ cell cancer | MNDR-E-MI-54949 |
| MNDR | hsa-miR-497-5p | Breast invasive carcinoma | MNDR-E-MI-54950 |
| MNDR | hsa-miR-497-5p | Hepatocellular carcinoma | MNDR-E-MI-54951 |
| MNDR | hsa-miR-497-5p | Embryonal cancer | MNDR-E-MI-54952 |
| MNDR | hsa-miR-497-5p | Familiar ovarian carcinoma | MNDR-E-MI-54953 |
| MNDR | hsa-miR-497-5p | Rheumatoid arthritis | MNDR-E-MI-54954 |
| MNDR | hsa-miR-497-5p | Barrett's adenocarcinoma | MNDR-E-MI-54955 |
| MNDR | hsa-miR-497-5p | Hodgkin lymphoma | MNDR-E-MI-54956 |
| MNDR | hsa-miR-497-5p | Burkitt lymphoma | MNDR-E-MI-54957 |
| MNDR | hsa-miR-497-5p | Colorectal cancer | MNDR-E-MI-54958 |
| MNDR | hsa-miR-497-5p | Uterine cervical neoplasms | MNDR-E-MI-54959 |
| MNDR | hsa-miR-497-5p | Nasopharyngeal cancer | MNDR-E-MI-54960 |
| MNDR | hsa-miR-497-5p | Aids dementia complex | MNDR-E-MI-54961 |
| MNDR | hsa-miR-497-5p | Pancreatitis chronic | MNDR-E-MI-54962 |
| MNDR | hsa-miR-497-5p | Barrett's carcinogenesis | MNDR-E-MI-54963 |
| MNDR | hsa-miR-497-5p | Breast cancer her3+ negative | MNDR-E-MI-54964 |
| MNDR | hsa-miR-497-5p | Duke A | MNDR-E-MI-54965 |
| MNDR | hsa-miR-497-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-54966 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | AGO4 | Homo sapiens | RR00056018 |
TOP